Citadel Advisors’s CureVac CVAC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-54,500
| Closed | -$246K | – | 13158 |
|
|
2025
Q4 | $246K | Sell |
54,500
-1,900
| -3% | -$9.73K | ﹤0.01% | 10587 |
|
|
2025
Q3 | $304K | Buy |
56,400
+32,600
| +137% | +$176K | ﹤0.01% | 10342 |
|
|
2025
Q2 | $129K | Sell |
23,800
-6,300
| -21% | -$25K | ﹤0.01% | 11098 |
|
|
2025
Q1 | $83.4K | Sell |
30,100
-500
| -2% | -$1.74K | ﹤0.01% | 11712 |
|
|
2024
Q4 | $104K | Buy |
30,600
+7,400
| +32% | +$21.3K | ﹤0.01% | 11429 |
|
|
2024
Q3 | $68.2K | Buy |
23,200
+2,000
| +9% | +$6.59K | ﹤0.01% | 11592 |
|
|
2024
Q2 | $72.1K | Sell |
21,200
-200
| -0.9% | -$654 | ﹤0.01% | 11341 |
|
|
2024
Q1 | $64.8K | Sell |
21,400
-96,900
| -82% | -$340K | ﹤0.01% | 11912 |
|
|
2023
Q4 | $498K | Buy |
118,300
+5,900
| +5% | +$32K | ﹤0.01% | 8122 |
|
|
2023
Q3 | $768K | Buy |
112,400
+39,700
| +55% | +$351K | ﹤0.01% | 7140 |
|
|
2023
Q2 | $758K | Sell |
72,700
-5,500
| -7% | -$49.2K | ﹤0.01% | 7040 |
|
|
2023
Q1 | $545K | Sell |
78,200
-63,600
| -45% | -$554K | ﹤0.01% | 8127 |
|
|
2022
Q4 | $855K | Buy |
141,800
+22,200
| +19% | +$164K | ﹤0.01% | 7115 |
|
|
2022
Q3 | $942K | Sell |
119,600
-55,200
| -32% | -$644K | ﹤0.01% | 7120 |
|
|
2022
Q2 | $2.38M | Buy |
174,800
+43,200
| +33% | +$715K | ﹤0.01% | 5212 |
|
|
2022
Q1 | $2.58M | Buy |
131,600
+9,200
| +8% | +$184K | ﹤0.01% | 5519 |
|
|
2021
Q4 | $4.2M | Sell |
122,400
-82,400
| -40% | -$3.32M | ﹤0.01% | 4646 |
|
|
2021
Q3 | $11.2M | Sell |
204,800
-218,100
| -52% | -$13.1M | ﹤0.01% | 2888 |
|
|
2021
Q2 | $31.1M | Buy |
422,900
+310,600
| +277% | +$31M | 0.01% | 1575 |
|
|
2021
Q1 | $10.3M | Buy |
112,300
+43,200
| +63% | +$4.19M | ﹤0.01% | 2924 |
|
|
2020
Q4 | $5.6M | Sell |
69,100
-4,500
| -6% | -$344K | ﹤0.01% | 3502 |
|
|
2020
Q3 | $3.43M | Buy |
+73,600
| New | +$4.11M | ﹤0.01% | 3750 |
|
Citadel Advisors's CVAC Position: Q1 2026 in Review
Citadel Advisors sold out of CureVac (CVAC) in Q1 2026, closing a stake of 261,097 shares — an estimated $1.18M sold.
Citadel Advisors first reported a position in CVAC in Q4 2020 and held it in 18 quarters. The position peaked at $24.5M in Q2 2023. 0 funds tracked by Wall St. Rank hold CVAC as of Q1 2026.
- Citadel Advisors reported no remaining CureVac position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 261,097 CureVac shares in Q1 2026, an estimated $1.18M.
- Citadel Advisors first reported a position in CureVac in Q4 2020 and held it in 18 quarters.
- Citadel Advisors's CureVac position peaked at $24.5M in Q2 2023.
- 0 funds tracked by Wall St. Rank held CureVac as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.